As long as the chimeric protein is able to hone to the tumor, it will be able to coat the tumor with E7 antigenic peptide, rendering them susceptible to the E7 antigen-specific CD8+ T cell-mediated killing. The gene discussed is CD8A; the disease is neoplasm.